661 related articles for article (PubMed ID: 23628959)
1. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
2. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
3. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
4. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
5. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
6. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
7. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C
Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472
[TBL] [Abstract][Full Text] [Related]
9. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
10. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
11. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
12. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
[TBL] [Abstract][Full Text] [Related]
14. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
15. Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
[TBL] [Abstract][Full Text] [Related]
16. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
17. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
18. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
19. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract][Full Text] [Related]
20. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]